Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,476 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Birmingham, AlabamaAges 12 years+ - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Phoenix, ArizonaAges 12 years+ - NCT07672561RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This study tests an experimental pill called WD-890 to see if it can help people with moderate to severe plaque psoriasis. The pill is compared to a placebo (a pill with no medicine) to check if it is safe and works well.
Nanjing, JiangsuAges 18–75 - NCT06258668Recruiting
Real-world study of Sotyktu for psoriasis in Korea
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
SeoulAges 19 years+ - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT07616648Recruiting
How Opioid Pain Drugs Affect Sleep and Mood in Cancer Patients
This study examines how opioid medications (strong pain relievers) impact sleep quality and emotional well-being in cancer patients with moderate to severe pain. Researchers will track your sleep patterns and mood to better understand these side effects.
HangzhouAges 18–75 - NCT07614191RecruitingEarly Phase 1
GT801 Cell Therapy for Hard-to-Treat Autoimmune Diseases
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07564505RecruitingPhase 4
Adalimumab Safety and Effectiveness in Children With Crohn's Disease
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
Guangzhou, GuangdongAges 6–17 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT07444801Recruiting
Tralokinumab for eczema with genital symptoms
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Augsburg, MünchenAges 18 years+ - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT07372287RecruitingPhase 3
Study of CM326 for moderate to severe asthma
This trial tests an investigational drug called CM326 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if CM326 can help reduce asthma attacks and improve breathing.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07370909RecruitingPhase 3
Oral LW402 for moderate-to-severe eczema
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
BeijingAges 18–75 - NCT07370766Recruiting
Tildrakizumab for moderate-to-severe psoriasis in Canada
This study looks at how well tildrakizumab works for people with moderate-to-severe plaque psoriasis who are starting this treatment through a support program in Canada. Researchers want to see how it affects your symptoms and daily life.
Burlington, OntarioAges 18 years+ - NCT07362017RecruitingPhase 3
Ponesimod for moderate to severe plaque psoriasis
This trial tests an investigational drug called ponesimod for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at improving skin symptoms.
Glendale, ArizonaAges 18–65 - NCT07363694RecruitingPhase 2/Phase 3
Study of PF-07275315 for moderate to severe COPD
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
Birmingham, AlabamaAges 35–80 - NCT07333118RecruitingEarly Phase 1
Testing GT801 for severe autoimmune diseases
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT07300384Recruiting
Blood flow restriction training for knee pain relief before surgery
This study tests whether a special type of strength training (called blood flow restriction training) can reduce pain in people with severe knee arthritis who are waiting for knee replacement surgery. The training uses a cuff on the thigh to lightly restrict blood flow while doing exercises until failure.
Valencia, ValenciaAges 50–85 - NCT06560372Recruiting
Bleeding after head injury and brain blood vessel narrowing
This study looks at whether moderate to severe traumatic brain injury with bleeding around the brain can lead to a complication called cerebral vasospasm (narrowing of brain blood vessels). It's being done at Martinique University Hospital to understand how often this happens and how it affects recovery.
Fort-de-FranceAges 18 years+ - NCT07234591Recruiting
Study of an oral medication for moderate to severe plaque psoriasis
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
ShanghaiAges 18–70 - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07169695RecruitingPhase 2
Comparing a new eye drop to cyclosporine for eye allergy in kids
This study tests a new eye drop (T1695) against cyclosporine for children with moderate to severe vernal keratoconjunctivitis, a type of eye allergy. It aims to see which treatment works better and is safer for reducing symptoms.
Kolkata, West BengalAges 4–17 - NCT07158242RecruitingPhase 3
Study of a Medication for Children with Active Ulcerative Colitis
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
Aurora, ColoradoAges 2–17
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,476 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.